The utility of animal models to evaluate novel anti-obesity agents.
The global incidence of obesity continues to rise and is a major driver of morbidity and mortality through cardiovascular and cerebrovascular diseases. Animal models used in the discovery of novel treatments for obesity range from straightforward measures of food intake in lean rodents to long-term studies in animals exhibiting obesity due to the continuous access to diets high in fat. The utility of these animal models can be extended to determine, for example, that weight loss is due to fat loss and/or assess whether beneficial changes in key plasma parameters (e.g. insulin) are evident. In addition, behavioural models such as the behavioural satiety sequence can be used to confirm that a drug treatment has a selective effect on food intake. Typically, animal models have excellent predictive validity whereby drug-induced weight loss in rodents subsequently translates to weight loss in man. However, despite this, at the time of writing orlistat (Europe; USA) remains the only drug currently marketed for the treatment of obesity, with sibutramine having recently been withdrawn from sale globally due to the increased incidence of serious, non-fatal cardiovascular events. While the utility of rodent models in predicting clinical weight loss is detailed, the review also discusses whether animals can be used to predict adverse events such as those seen with recent anti-obesity drugs in the clinic.
RenaSci Consultancy Ltd, BioCity, Nottingham, UK.
Steven P
SP
Vickers
Helen C
HC
Jackson
Sharon C
SC
Cheetham
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D001067:Appetite Depressants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D004195:Disease Models, Animal; D005247:Feeding Behavior / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology / Q000503:physiopathology; D012528:Satiety Response / Q000187:drug effects; D013997:Time Factors
D019440:Anti-Obesity Agents; D001067:Appetite Depressants
Auton Neurosci. 2006 Oct 30;129(1-2):36-41
16950662
N Engl J Med. 1997 Aug 28;337(9):581-8
9271479
Hypertension. 2009 Feb;53(2):251-5
19114642
Br J Pharmacol. 1999 Mar;126(6):1487-95
10217544
Neurosci Biobehav Rev. 1987 Spring;11(1):107-30
3554039
Diabet Med. 2010 Oct;27(10):1168-73
20854385
Neuroreport. 1997 Jan 20;8(2):491-6
9080435
Psychopharmacology (Berl). 1994 Jan;113(3-4):369-77
7862847
Rev Endocr Metab Disord. 2001 Oct;2(4):403-18
11725727
Psychopharmacology (Berl). 2003 May;167(3):274-80
12690422
Behav Brain Res. 2009 Mar 17;198(2):359-65
19061919
Int J Obes (Lond). 2010 Feb;34(2):385-95
19935749
Eur J Pharmacol. 2003 Aug 15;475(1-3):37-47
12954357
Obesity (Silver Spring). 2008 Apr;16(4):811-8
18239588
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83
9238071
Arch Fam Med. 2000 Feb;9(2):160-7
10693734
Neurosci Lett. 2003 Jun 12;343(3):216-8
12770700
Int J Obes. 1987;11 Suppl 3:35-42
3440690
J Pharmacol Exp Ther. 2006 Jul;318(1):304-11
16569753
J Pharmacol Exp Ther. 2005 Apr;313(1):395-402
15590770
Life Sci. 1998;63(8):PL113-7
9718088
J Appl Physiol. 1975 Nov;39(5):849-50
1184527
Br J Pharmacol. 2000 Jul;130(6):1305-14
10903970
Psychopharmacology (Berl). 1999 Apr;143(3):309-14
10353435
Dis Model Mech. 2010 Mar-Apr;3(3-4):156-66
20212084
Biol Psychiatry. 2005 Feb 1;57(3):261-7
15691527
Curr Drug Targets. 2005 Mar;6(2):215-23
15777191
J Pharmacol Exp Ther. 2008 May;325(2):577-87
18252809
Pharmacol Biochem Behav. 2010 Nov;97(1):3-14
20214921
Pharmacol Ther. 2008 Feb;117(2):207-31
18068807
Am J Physiol. 1997 Feb;272(2 Pt 2):R726-30
9124501
Endocrinology. 2008 Nov;149(11):5679-87
18669592
J Mol Endocrinol. 2006 Jun;36(3):485-501
16720718
Diabetes Obes Metab. 2007 May;9(3):259-75
17391151
Obesity (Silver Spring). 2009 Jan;17(1):30-9
18997675
Philos Trans R Soc Lond B Biol Sci. 2006 Jul 29;361(1471):1251-63
16815802
Nat Med. 1995 Nov;1(11):1155-61
7584987
Clin Sci (Lond). 2001 Jun;100(6):635-41
11352779
Br J Pharmacol. 2006 Aug;148(7):973-83
16783408
Psychopharmacology (Berl). 2003 Apr;167(1):103-11
12632249
Neuropharmacology. 2001 Aug;41(2):200-9
11489456
Pharmacol Biochem Behav. 2006 Jun;84(2):353-9
16814374
Am J Clin Nutr. 1998 Dec;68(6):1180-6
9846844
Lancet. 2000 Dec 23-30;356(9248):2119-25
11191537
Am J Clin Nutr. 1997 May;65(5 Suppl):1590S-1596S
9129499
Ann Nutr Metab. 2010;56(2):127-42
20134158
J Endocrinol. 2010 Sep;206(3):287-96
20508079
PLoS Genet. 2006 Dec 29;2(12):e188
17196040
JAMA. 1999 Oct 27;282(16):1568-75
10546697
Int J Obes Relat Metab Disord. 1998 Jul;22(7):619-23
9705019
Clin Neuropharmacol. 1988;11 Suppl 1:S121-34
3180107
Am J Clin Nutr. 2009 Jun;89(6):1723-8
19369382
Mol Pharmacol. 2003 Dec;64(6):1295-308
14645659
Br J Clin Pharmacol. 2009 Dec;68(6):861-74
20002080
J Med Chem. 2008 Jan 24;51(2):305-13
18095642
Adv Ther. 2006 Nov-Dec;23(6):1016-29
17276969
Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):353-8
19625958
Pharmacol Biochem Behav. 2010 Nov;97(1):63-83
20688100
Br J Nutr. 2007 Jun;97(6):1099-108
17397561
Diabetes. 2002 May;51(5):1337-45
11978628
J Pharm Pharmacol. 2009 Nov;61(11):1493-8
19903374
Am J Clin Nutr. 2009 Mar;89(3):980S-984S
19211814
Am J Med. 1999 Feb;106(2):179-84
10230747
J Neurosci. 2000 Feb 15;20(4):1616-21
10662851
Psychopharmacology (Berl). 1996 May;125(2):168-75
8783391
Physiol Behav. 2003 Sep;79(4-5):761-6
12954420
Psychopharmacology (Berl). 2007 Nov;195(1):27-39
17639351
Br J Pharmacol. 1997 Aug;121(8):1758-62
9283714
Int J Obes (Lond). 2006 Sep;30(9):1332-40
16534527
Methods Find Exp Clin Pharmacol. 1995 Nov;17(9):589-90
8786672
Neurosci Lett. 2004 Jan 16;354(3):217-20
14700735
Nat Clin Pract Endocrinol Metab. 2008 Oct;4(10):569-77
18779842
Thyroid. 1995 Dec;5(6):481-92
8808101
Obes Res. 2003 Jun;11(6):722-33
12805393
J Comp Physiol Psychol. 1975 Sep;89(7):784-90
1176672
Int J Obes Relat Metab Disord. 1999 Oct;23(10):1009-15
10557020
Int J Obes Relat Metab Disord. 1999 Oct;23(10):1016-24
10557021
Br Heart J. 1993 Dec;70(6):537-41
8280518
Nature. 1994 Dec 1;372(6505):425-32
7984236
N Engl J Med. 2005 Nov 17;353(20):2121-34
16291982
Int Rev Neurobiol. 2011;96:73-109
21329785
JAMA. 2006 Feb 15;295(7):761-75
16478899
Endocr Rev. 2000 Dec;21(6):697-738
11133069
Obesity (Silver Spring). 2009 Sep;17(9):1736-43
19521351
Pharmacol Biochem Behav. 2001 Sep;70(1):123-31
11566149
Hypertension. 2005 Apr;45(4):602-7
15723966
Nature. 1997 Jun 26;387(6636):903-8
9202122
Nature. 1995 Apr 6;374(6522):542-6
7700379
BMC Pharmacol. 2010 Aug 16;10:9
20712891
Obes Rev. 2006 Feb;7(1):89-108
16436105
Methods Find Exp Clin Pharmacol. 2002 Apr;24(3):135-8
12087874
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53
12399252
Experientia. 1959 Nov 15;15:444-5
14421993
Am J Physiol. 1997 Aug;273(2 Pt 2):R725-30
9277561
Mini Rev Med Chem. 2007 Jan;7(1):31-8
17266635
Nat Rev Genet. 2005 Mar;6(3):221-34
15703762
Behav Pharmacol. 2005 Sep;16(5-6):315-31
16148437
Proc Natl Acad Sci U S A. 2008 May 20;105(20):7257-62
18458326
J Hered. 1950 Dec;41(12):317-8
14824537
Eur J Pharmacol. 2003 Jul 18;473(1):41-6
12877936
Drug Alcohol Depend. 2003 Jun 5;70(3 Suppl):S55-72
12759197
Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95
20385125
Vet Pathol. 2009 Jan;46(1):10-24
19112110
Nat Rev Endocrinol. 2010 May;6(5):255-69
20234354
Neurobiol Dis. 2010 Aug;39(2):148-55
20381618
Nature. 1998 Mar 26;392(6674):398-401
9537324
Curr Opin Endocrinol Diabetes Obes. 2010 Apr;17(2):143-9
20160646
Am J Physiol Endocrinol Metab. 2000 Aug;279(2):E340-7
10913034
Diabetes. 2003 Mar;52(3):682-7
12606509
Lancet. 2005 Apr 16-22;365(9468):1389-97
15836887
Pharmacol Biochem Behav. 2002 Apr;71(4):691-700
11888560
Psychopharmacology (Berl). 1989;97(2):213-8
2498930
Methods Find Exp Clin Pharmacol. 1995 Dec;17(10):647-52
9053584
Pharmacol Biochem Behav. 1998 Oct;61(2):159-68
9738531
N Engl J Med. 2010 Jul 15;363(3):245-56
20647200
Nutr Rev. 1978 May;36(5):129-32
355940
Pharmacol Biochem Behav. 1993 Aug;45(4):817-21
8415820
Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1634-41
18708447